| Designing a broad-spectrum integrative approach for cancer prevention and treatment KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35, S276-S304, 2015 | 302 | 2015 |
| Calcium activates serum response factor-dependent transcription by a Ras-and Elk-1-independent mechanism that involves a Ca2+/calmodulin-dependent kinase CK Miranti, DD Ginty, G Huang, T Chatila, ME Greenberg Molecular and cellular biology, 1995 | 271 | 1995 |
| Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors GS Huang, JS Gebb, MH Einstein, S Shahabi, AP Novetsky, GL Goldberg American journal of obstetrics and gynecology 196 (3), 243. e1-243. e5, 2007 | 164 | 2007 |
| Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds ARMR Amin, PA Karpowicz, TE Carey, J Arbiser, R Nahta, ZG Chen, ... Seminars in cancer biology 35, S55-S77, 2015 | 141 | 2015 |
| Total laparoscopic hysterectomy: body mass index and outcomes KA O'Hanlan, L Lopez, SL Dibble, AC Garnier, GS Huang, ... Obstetrics & Gynecology 102 (6), 1384-1392, 2003 | 134 | 2003 |
| Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer GS Huang, J Brouwer-Visser, MJ Ramirez, CH Kim, TM Hebert, J Lin, ... Clinical Cancer Research 16 (11), 2999-3010, 2010 | 128 | 2010 |
| IGF2 signaling and regulation in cancer J Brouwer-Visser, GS Huang Cytokine & growth factor reviews 26 (3), 371-377, 2015 | 123 | 2015 |
| Potentiation of taxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice GS Huang, L Lopez-Barcons, BS Freeze, AB Smith III, GL Goldberg, ... Clinical cancer research 12 (1), 298-304, 2006 | 117 | 2006 |
| Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma GS Huang, LG Chiu, JS Gebb, MJ Gunter, P Sukumvanich, GL Goldberg, ... Gynecologic oncology 107 (3), 513-517, 2007 | 97 | 2007 |
| Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer N Colombo, G Huang, G Scambia, E Chalas, S Pignata, J Fiorica, ... Journal of Clinical Oncology 36 (13), 1300-1307, 2018 | 96 | 2018 |
| Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial MB Ortigoza, H Yoon, KS Goldfeld, AB Troxel, JP Daily, Y Wu, Y Li, D Wu, ... JAMA internal medicine 182 (2), 115-126, 2022 | 73 | 2022 |
| Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy L Zammataro, S Lopez, S Bellone, F Pettinella, E Bonazzoli, E Perrone, ... Proceedings of the National Academy of Sciences 116 (45), 22730-22736, 2019 | 66 | 2019 |
| A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma C Han, S Bellone, ER Siegel, G Altwerger, G Menderes, E Bonazzoli, ... Gynecologic oncology 149 (3), 585-591, 2018 | 64 | 2018 |
| Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma MH Einstein, M Frimer, DYS Kuo, LL Reimers, K Mehta, S Mutyala, ... Gynecologic oncology 124 (1), 21-25, 2012 | 62 | 2012 |
| Total laparoscopic hysterectomy versus total abdominal hysterectomy: cohort review of patients with uterine neoplasia KA O'Hanlan, GS Huang, AC Garnier, SL Dibble, ML Reuland, L Lopez, ... JSLS: Journal of the Society of Laparoendoscopic Surgeons 9 (3), 277, 2005 | 62 | 2005 |
| Integrated mutational landscape analysis of uterine leiomyosarcomas J Choi, A Manzano, W Dong, S Bellone, E Bonazzoli, L Zammataro, X Yao, ... Proceedings of the National Academy of Sciences 118 (15), e2025182118, 2021 | 60 | 2021 |
| Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma GS Huang, MJ Gunter, RC Arend, M Li, H Arias-Pulido, ER Prossnitz, ... American journal of obstetrics and gynecology 203 (3), 242. e1-242. e5, 2010 | 56 | 2010 |
| Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors C Li, E Bonazzoli, S Bellone, J Choi, W Dong, G Menderes, G Altwerger, ... Proceedings of the National Academy of Sciences 116 (2), 619-624, 2019 | 54 | 2019 |
| SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression G Menderes, E Bonazzoli, S Bellone, J Black, G Altwerger, A Masserdotti, ... Gynecologic oncology 146 (1), 179-186, 2017 | 52 | 2017 |
| Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma MH Einstein, M Klobocista, JY Hou, S Lee, S Mutyala, K Mehta, ... Gynecologic oncology 124 (1), 26-30, 2012 | 52 | 2012 |
